As part of its acquisition of TargeTech Inc., Immune ResponseCorp. has filed a registration statement with the Securities andExchange Commission covering almost 1.27 million shares ofcommon stock that was previously issued to former securityholders of the private gene therapy company.

TargeTech of Meriden, Conn., became a wholly ownedsubsidiary of Immune Response last November.

Immune Response (NASDAQ:IMNR) of Carlsbad, Calif., hadplanned to pay $3 million in cash and issue 1.33 million sharesof common stock to acquire TargeTech, but spokeswoman CindyRollins said less stock was issued because some options wereincluded.

TargeTech has developed in vivo gene therapy technology tointroduce therapeutic genes to liver cells via a ligand. Theacquisition expanded Immune Response's technology basebeyond its own concentration in HIV infection and autoimmunediseases.

(c) 1997 American Health Consultants. All rights reserved.